Navigation Links
Ikaria® Names New Chief Financial Officer
Date:7/8/2010

CLINTON, N.J., July 8 /PRNewswire/ -- Ikaria, Inc. today announced that Craig Tooman will join Ikaria as Senior Vice President and Chief Financial Officer (CFO).  In this role, Mr. Tooman will be responsible for all financial functions of the company, as well as for information technology services.  Mr. Tooman succeeds Elizabeth Larkin, who left the company in March to pursue other interests.  He will assume his new role at the beginning of August.

"I am delighted that Craig will join us in this key executive role, and am confident that we will benefit greatly from his knowledge and experience in effectively managing the financial aspects of our business," commented Daniel Tasse, Chairman and CEO of Ikaria. "I believe that Craig's expertise -- combined with our product pipeline and commercial capabilities -- will help us achieve our vision of becoming a leader in critical care.  I also wish to thank Liz for building a strong foundation from which we can build."

Mr. Tooman has over 20 years of experience in the pharmaceutical industry, and joins Ikaria from Enzon Pharmaceuticals, where he was Executive Vice President of Finance and CFO since 2005.  Prior to joining Enzon, he served as Senior Vice President of Strategic Planning and Corporate Communications at ILEX Oncology, Inc., which was acquired by Genzyme in 2004.  He also played a significant role in the 2001 merger between Pharmacia & Upjohn and Monsanto that created the Pharmacia Corporation, having served in various positions within its predecessor companies Pharmacia & Upjohn and The Upjohn Company.  Mr. Tooman holds an MBA from the University of Chicago, and a BA from Kalamazoo College.

About Ikaria, Inc.

Ikaria, Inc. is a biotherapeutics company focused on developing and commercializing innovative therapeutics and interventions designed to address the significant unmet needs of critically ill patients.  The company's lead product is INOtherapy®, an all-inclusive offering of drug product, services and technologies.  INOMAX® (nitric oxide) for inhalation, the drug included in the INOtherapy offering, is the only FDA-approved drug for the treatment of hypoxic respiratory failure associated with pulmonary hypertension in term and near-term infants.  INOtherapy also is marketed in Puerto Rico, Canada, Australia, Mexico and Japan.  Ikaria acquired the North American and Australian rights to LUCASSIN® (terlipressin), a potential treatment for hepatorenal syndrome Type 1, as well as the exclusive worldwide license to IK-5001, a potential treatment for preventing cardiac remodeling and subsequent congestive heart failure following acute myocardial infarction.  The company also has a number of investigational compounds in development.  Ikaria is headquartered in Clinton, NJ, with research facilities in Seattle, WA and Madison, WI, and a manufacturing facility in Port Allen, LA.  Please visit www.ikaria.com.


'/>"/>
SOURCE Ikaria, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AIDS Healthcare Foundation Names Homayoon Khanlou, M.D. as its Chief of Medicine, U.S.
2. Global HIV Vaccine Enterprise Names Alan Bernstein as Inaugural Executive Director, Opens New Secretariat
3. Xytis Names Gordon H. Busenbark as Chief Financial Officer
4. PLC Medical Systems Names Lead Investigators for Pivotal Trial to Evaluate RenalGuard System(TM) and RenalGuard Therapy(TM)
5. Association of Clinical Research Organizations (ACRO) Names Dr. Derek Winstanly Chair-Elect
6. California Cryobank Names Richard Jennings President of FamilyCord Division
7. Zeltiq Aesthetics Names Gordie Nye to Serve as New CEO
8. ParagonRx Names Ellen M. Derrico To Chief Marketing Executive Post
9. Boston Business Journal Names NxStage(R) Medical Third Fastest Growing Company in Massachusetts
10. NovaBay Pharmaceuticals Expands Management Team; Names Mark Anderson, Ph.D. as Chief Scientific Officer
11. ThermoGenesis Names Jorge Artiles Vice President, Chief Quality and Regulatory Affairs Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , 22 de marzo de 2017   ... líder de soluciones de productos y servicios para ... que ha adquirido EPL Archives, Inc., una organización ... clientes en todo el ciclo de vida de ... una muestra de archivo, almacenamiento de documentos y ...
(Date:3/22/2017)... CAESAREA, Israel, March 22, 2017  DarioHealth Corp. ... with mobile health and big data solutions, today ... and twelve month period ended December 31, 2016. ... revenues of $2.8 million, increased 241% compared to ... quarterly revenue growth throughout the entire year  ...
(Date:3/22/2017)... , March 22, 2017 Ampio Pharmaceuticals, ... development of Ampion™, a low molecular weight fraction ... announced that it is re-issuing its previous release that ... certain disclosures that are required under the NYSE ... are these additional disclosures along with the previously ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... The Boulevard is honored ... 2pm. All events will be located in the Main West Entrance of The ... Child ID event. No appointment is necessary and each child with a parent or ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... “Wounded Woman ... “Wounded Woman Be Ye Healed-Passing On A Legacy” is the creation of published author, ... founder of Comfortbearers grief ministry. She has been happily married to her husband, ...
(Date:3/23/2017)... ... ... “The Trainer”: an electrifying and suspenseful gunslinger novel with a twist. “The ... imagination and an enthusiasm for action and adventure stories. , Published by ... sat looking at the thirty-three notches that lined the edges of the wooden grip ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... publication of the first issue of its companion print magazine. The new magazine, ... cosmetic surgery thanks to information provided by board-certified doctors from across the country. ...
(Date:3/22/2017)... ... March 22, 2017 , ... The ... inhibitor prior authorization (PA) form for prescribers to improve patients’ access to the ... helpful tools published as part of the article entitled “PCSK9 Inhibitor Access ...
Breaking Medicine News(10 mins):